Sally Kilbride - Concepedia

Author

Sally Kilbride

Research Triangle Park Foundation ORCID

Also Known As

Kilbride S, S Kilbride, S. Kilbride, SALLY KILBRIDE, Sally Kilbride

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Research Triangle Park Foundation GlaxoSmithKline (United States)GlaxoSmithKline (United Kingdom)Cornell University Johns Hopkins Medicine

About

Sally Kilbride is an author at Research Triangle Park Foundation specializing in medicine, pulmonary disease, and pulmonary medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	221
2	Pulmonary Disease	3	3	221
3	Pharmacology	2	2	185
4	Pulmonary Medicine	2	2	191
5	Allergy	1	1	36

Sally Kilbride

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD David A. Lipson, Frank Barnhart, Noushin Brealey, New England Journal of Medicine	2018	1.2K
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease David A. Lipson, Courtney Crim, Gerard J. Criner, American Journal of Respiratory and Critical Care Medicine	2020	237
Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD Bartolomé R. Celli, Glenn Crater, Sally Kilbride, CHEST Journal Umeclidinium/vilanterol 125/25Pulmonary CareAdvanced Lung DiseaseMedicinePulmonary Medicine	2014	155
Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: A randomised trial Fernando J. Martínez, Joseph Boscia, Gregory Feldman, Respiratory Medicine	2013	139
Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials James F. Donohue, Dave Singh, Clara Munzu, Respiratory Medicine	2016	64
Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk Peter M.A. Calverley, Julie A. Anderson, Robert D. Brook, American Journal of Respiratory and Critical Care Medicine	2017	61
Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction Fernando J. Martínez, Jørgen Vestbo, Julie A. Anderson, American Journal of Respiratory and Critical Care Medicine	2016	52
The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial MeiLan K. Han, Gerard J. Criner, Mark T. Dransfield, American Journal of Respiratory and Critical Care Medicine	2020	39
The effect of exacerbation history on outcomes in the IMPACT trial David Halpin, Mark T. Dransfield, MeiLan K. Han, European Respiratory Journal	2020	38
Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial Courtney Crim, Peter M.A. Calverley, Julie A. Anderson, Respiratory Medicine AsthmaAllergyAdvanced Lung DiseaseRespiratory DiseasesPulmonary Fibrosis	2017	36

Page 1